IMA - NASDAQ

II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Shares Outstanding

Last Annual Value

4.87M

3-Year CAGR

-49%

5-Year CAGR

-19%

10-Year CAGR

-18%

II

ImageneBio Inc Competitors Analysis of shares-outstanding

IMA · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
4.87M
-51.1%-33.0%N/A 
QNCX logo
Quince Therapeutics, Inc.
NASDAQ:QNCX
43.26M
5.1%7.8%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
6.89M
36.8%28.9%-13.1%
HYFT logo
MindWalk Holdings Corp.
NASDAQ:HYFT
33.38M
10.3%15.2%32.5%
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
15.57M
52.0%45.8%34.8%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
10.61M
10.1%6.0%5.8%
UNCY logo
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
158.87M
301.5%167.1%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
230.35M
-22.1%-13.9%20.7%
STRO logo
Sutro Biopharma, Inc.
NASDAQ:STRO
8.50M
12.2%13.0%34.4%
OVID logo
Ovid Therapeutics Inc.
NASDAQ:OVID
73.74M
1.5%1.6%14.2%
KLRS logo
Kalaris Therapeutics Inc
NASDAQ:KLRS
15.27M
50.0%41.1%N/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

HIDDEN
Intrinsic Value
Current Price: $5.69

Related Guides

Blog Categories

Continue your IMA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.